Lisdexamfetamine Dimesylate Demonstrates Significantly Faster Response, Greater Reductions Of Core ADHD Symptoms Than Atomoxetine In Study

Shire plc (LSE: SHP, NASDAQ: SHPG) presents scientific data comparing the efficacy and safety of the Attention Deficit/Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) at the 4th World Congress on ADHD, Milan, Italy. The study (SPD489-317) is the first head-to-head trial in children and adolescents with at least moderately symptomatic ADHD and an inadequate response to previous methylphenidate therapy...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: ADHD Source Type: news